Danielsson A, Nilsson T K, Uddenfeldt P
Dept. of Medicine, University Hospital of Umeå, Sweden.
Scand J Gastroenterol. 1990 Feb;25(2):149-54. doi: 10.3109/00365529009107936.
C1 inhibitor and von Willebrand factor (vWF) levels were studied in patients with cholestatic or hepatocellular liver diseases. The vWF levels were greatly increased in hepatocellular liver diseases, whereas C1 inhibitor levels were slightly reduced. In cholestatic disease both the vWF and the C1 inhibitor levels were increased: among patients with primary biliary cirrhosis these increases were more pronounced in symptomatic patients than in asymptomatic ones. When compared with other protease inhibitors, the C1 inhibitor pattern in liver disease most closely resembled that of alpha 1-antitrypsin. Thus, C1 inhibitor levels cannot be used as a measure of residual hepatocyte mass in PBC; our data, however, suggested that antithrombin may be more suitable for that purpose.
对胆汁淤积性或肝细胞性肝病患者的C1抑制因子和血管性血友病因子（vWF）水平进行了研究。肝细胞性肝病患者的vWF水平大幅升高，而C1抑制因子水平略有降低。在胆汁淤积性疾病中，vWF和C1抑制因子水平均升高：在原发性胆汁性肝硬化患者中，有症状患者的这些升高比无症状患者更为明显。与其他蛋白酶抑制剂相比，肝病中的C1抑制因子模式与α1-抗胰蛋白酶最为相似。因此，C1抑制因子水平不能用作原发性胆汁性肝硬化中残余肝细胞量的指标；然而，我们的数据表明抗凝血酶可能更适合用于此目的。
